

Corrections to Pediatric ARV Treatment Guidelines

On November 5, 2012, corrections were made to the [Pediatric ARV Treatment Guidelines](#) (released November 1, 2012) to correct the following errors:

- In [What's New in the Guidelines?](#), under *What Drugs to Start*, the phrase “oral granules” (erroneously used to describe raltegravir) has been removed.
- In the [Appendix A](#) record for [raltegravir](#), under *Pediatric Use*, the GM 12 h concentration cited has been changed from “13 nM” to “>33 nM.” The statement now correctly reads:
 - Dose selection was based upon achieving target PK parameters similar to those seen in adults: PK targets are geometric mean (GM) area under the curve of 14–25 µMxh and GM 12 h concentration >33 nM.

On November 15, 2012, additional changes were made to the [Pediatric ARV Treatment Guidelines](#) (released November 1, 2012):

- In [Regimens Recommended for Initial Therapy of Antiretroviral-Naive Children](#), in Table 8, ETV was erroneously used as the abbreviation for etravirine. The table was amended with the correct abbreviation, ETR.
- In the [Appendix A](#) record for [etravirine](#), table title for pediatric dosing was updated to include weight with the age restriction. The title now reads:
 - Antiretroviral-experienced children and adolescents aged 6–18 years and weighing at least 16 kg.
- In the [Appendix A](#) record for [etravirine](#), the statement advising against co-administering etravirine with other antiretroviral agents has been updated to include rilpivirine. The statement now reads:
 - It should not be administered with other non-nucleoside reverse transcriptase inhibitors (NNRTIs) (nevirapine, efavirenz, or rilpivirine).